Rapt Therapeutics (NASDAQ:RAPT) will collaborate with South Korea’s Hanmi Pharmaceutical Co., Ltd. to develop and commercialize cancer candidate FLX475, a CCR4 antagonist, in Asia.
Under the terms of the agreement, RAPT will receive $10M upfront, up the $48M in development milestones, up to $60M in sales milestones and double-digit royalties on net sales. Hanmi will have an exclusive license to FLX475 in South Korea and China (including Taiwan and Hong Kong).
Shares up 12% after hours.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.